A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs GS 0976 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Gilead Sciences; Nimbus Therapeutics
- 24 Oct 2017 Results published in a Gilead Sciences Media Release.
- 24 Oct 2017 According to a Gilead Sciences media release, results were presented at The Liver Meeting 2017.
- 03 Aug 2017 Status changed from active, no longer recruiting to completed.